查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2141693

臨床實驗新藥（IND）CDMO市場：全球市場預測，2026-2032年

Investigational New Drug CDMO Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，臨床實驗新藥 (IND) CDMO 市場將成長至 1,397,230,000 美元，複合年成長率為 8.52%。

主要市場統計數據
基準年 2025 7.8788億美元
預計年份：2026年 8.4682億美元
預測年份 2032 1,397,230,000 美元
複合年成長率 (%) 8.52%

臨床實驗新藥（IND）CDMO市場概覽

合約研發生產機構 (CDMO) 為臨床實驗藥物的申辦者提供從臨床前開發到臨床試驗樣本生產、分析測試、法規合規準備和技術轉移的全方位支援。隨著製藥公司在追求更複雜的分子、更專業的給藥系統和更快的研發進度的同時，還要兼顧品質、產能和合規性要求，CDMO 的角色日益重要。

外包、日益複雜的系統和更嚴格的監管正在改變開發的方式。

由於贊助商要求整合製程開發、分析服務、臨床生產、包裝和物流，產業趨勢正轉向一體化外包。生物製藥、細胞和基因療法、高活性化合物和無菌產品等複雜療法需要專門的設施、先進的防護措施和經驗豐富的品管團隊。監管機構對資料完整性、可比性、驗證、可追溯性和供應鏈管理的要求也在不斷提高，這使得技術專長和檢驗能力成為關鍵的選擇標準。

人工智慧正在提升研發和製造決策能力。

人工智慧正被應用於CDMO（合約研發生產機構）整體與臨床實驗藥物（IND）相關的活動中，包括分子和製程表徵、製劑最佳化、分析資料審查、偏差調查、需求計畫和設備維護。機器學習工具有助於改善製程變數的識別和實驗優先排序，而自然語言處理系統則有助於文件審查和知識搜尋。然而，人工智慧的應用仍取決於資料品質、模型驗證、網路安全、人工監督以及對電腦系統和電子記錄相關適用要求的遵守情況。

區域趨勢反映了它們在科學、監管和製造方面的各自優勢。

北美擁有強大的生物製藥創新能力、成熟的臨床試驗基礎設施和嚴格的監管要求。歐洲受惠於成熟的製藥能力、專業的生產技術以及跨境研發網路。亞太地區以其不斷提升的科研能力、活性化的臨床研發活動以及日益完善的生產生態系統而自豪。拉丁美洲受惠於不斷增強的研發和生產能力，但各國的監管和物流狀況卻不盡相同。中東正在投資生命科學基礎設施和醫療保健韌性建設，而非洲儘管在專業人才、基礎設施和監管能力方面面臨諸多限制，但也湧現出新的機會。

經濟和安全夥伴關係決定了外包的優先事項。

東南亞國協正在發展藥品生產、臨床研究和區域供應鏈的互補能力。金磚國家擁有重要的科學研究和生產資源以及龐大的患者群體，但在監管系統和基礎設施方面存在顯著差異。歐盟在推動監管協調的同時，也維持各自的國家實施要求。七國集團（G7）國家擁有先進的研究、專業的生產製造能力和嚴格的品管系統。海灣合作理事會（GCC）國家正在加強其在醫療保健和藥品領域的自給自足能力，而北約成員國則日益重視建立具有韌性、安全性和多元化的醫療產品供應鏈。

每個國家在創新、監管和生產規模方面的能力各不相同。

美國和加拿大擁有強大的生物技術生態系統、先進的臨床基礎設施和嚴格的監管體系。德國、法國、義大利、西班牙和英國在各自不同的國家架構內，具備強大的藥物研發、生產和專業服務能力。中國、日本、韓國、印度和澳洲在不斷發展的研發專長方面，擁有各自獨特的監管和營運環境。巴西和墨西哥是拉丁美洲的重要樞紐，其臨床和生產能力正在不斷提升。俄羅斯保持其科研和產業實力，但市場進入、合規性和國際供應鏈格局需要仔細評估。

優先考慮技術相容性、品質穩定性以及透明的夥伴關係模式。

產業領導企業應選擇與特定療法能力、研發階段、隔離要求、無菌需求和分析複雜性相符的合約研發生產力機構 (CDMO)。實質審查應評估其檢查歷史、品質系統、資料完整性、變更管理、產能可見度、員工隊伍深度、業務永續營運以及技術轉移記錄。專案發起人應儘早建立清晰的管治、品質協議、里程碑責任制和升級機制。他們還應在經過檢驗的控制措施下合理利用人工智慧，在實際可行的範圍內確保關鍵輸入資料的雙重來源或替代方案，並根據監管、物流和地緣政治要求評估區域合作夥伴。

調查方法。

本執行摘要根據臨床實驗藥物（IND）CDMO市場的既定範圍，按服務需求、技術應用、監管環境、地區和經濟群體對研究結果進行分類。摘要整合了成熟的行業實踐和公開記錄的與臨床開發和藥物生產相關的考慮因素，包括治療模式的複雜性、品管、供應鏈韌性和數位轉型。本摘要未使用任何市場規模估算或預測、市場佔有率、預測或公司特定聲明。

「執行能力」決定了能否與CDMO夥伴關係開發新的臨床實驗藥物。

臨床實驗製造機構（CDMO）正從單純的生產能力供應商轉型為策略開發合作夥伴。成功的關鍵在於其能否將專業的科學知識、可靠的臨床生產、強大的分析能力、嚴格的法規遵循以及穩健的營運管理融為一體。對於那些能夠根據產品複雜性、證據要求、地理風險和長期技術轉移需求做出客製化外包決策的申辦者而言，CDMO 將有助於其更有效率、合規地開發候選藥物。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章臨床實驗新藥 (IND) CDMO 市場：依服務類型分類

  • 分析測試
    • 分析測試方法的開發與驗證
    • 船舶檢驗
    • 穩定性測試
  • 臨床試驗藥物的生產
    • 第一/二期試驗樣品
    • 三期臨床試驗樣品
  • 商業生產
    • 大量生產
    • 連續製造
  • 配方開發
    • 冷凍乾燥製劑
    • 注射劑
    • 固態劑型
  • 包裝和標籤
  • 監理合規支持
    • CMC文件
    • IND申請支持

第8章臨床實驗新藥 (IND) CDMO 市場：依分子類型分類

  • 生物製劑
    • 細胞療法
    • 單株抗體
      • 抗體藥物複合體
      • 生物相似藥
    • 重組蛋白
    • 疫苗
  • 基因治療
  • 胜肽
  • 低分子化合物

第9章臨床實驗新藥（IND）CDMO市場：依治療領域分類

  • 心血管系統
  • 中樞神經系統
  • 免疫學
  • 感染疾病
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固體癌

第10章：臨床實驗新藥（IND）CDMO市場：依規模分類

  • 商業的
  • 第一/二期
  • 第三階段
  • 臨床前階段

第11章臨床實驗新藥 (IND) CDMO 市場：依生產類型分類

  • 批次
  • 連續型

第12章臨床實驗新藥（IND）CDMO市場：依許可模式分類

  • 聯合研究
  • 合約服務類型
  • 技術轉移

第13章臨床實驗新藥 (IND) CDMO 市場：依客戶類型分類

  • 學術機構
  • 生技公司
  • 製藥公司
  • 虛擬製藥

第14章臨床實驗新藥 (IND) CDMO 市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：臨床實驗新藥（IND）CDMO市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章臨床實驗新藥 (IND) CDMO 市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Adragos Pharma GmbH
  • AGC Biologics Inc.
  • Asymchem Laboratories Tianjin Co. Ltd.
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent Inc.
  • Charles River Laboratories International Inc.
  • CordenPharma International GmbH
  • Dishman Carbogen Amcis Limited
  • Eurofins Scientific SE
  • Evotec SE
  • Fujifilm Diosynth Biotechnologies Inc.
  • IQVIA Holdings Inc.
  • Laboratory Corporation of America Holdings
  • Lonza Group AG
  • PCI Pharma Services Inc.
  • Piramal Pharma Limited
  • Quotient Sciences Ltd.
  • Recipharm AB
  • Samsung Biologics Co. Ltd.
  • Siegfried Holding AG
  • Syneos Health Inc.
  • Syngene International Ltd.
  • Thermo Fisher Scientific Inc.
  • WuXi Biologics（Cayman）Inc.

第19章：關鍵專家

Product Code: MRR-9C4233EE5E2A

The Investigational New Drug CDMO Market is projected to grow by USD 1,397.23 million at a CAGR of 8.52% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 787.88 million
Estimated Year [2026] USD 846.82 million
Forecast Year [2032] USD 1,397.23 million
CAGR (%) 8.52%

Investigational New Drug CDMO Market: Executive Overview

Investigational new drug contract development and manufacturing organizations (CDMOs) support sponsors from preclinical development through clinical-trial material production, analytical testing, regulatory preparation, and technology transfer. Their role is increasingly important as drug developers pursue more complex molecules, specialized delivery systems, and faster development timelines while managing quality, capacity, and compliance requirements.

Outsourcing, Complexity, and Regulatory Rigor Are Reshaping Development

The landscape is shifting toward integrated outsourcing, with sponsors seeking coordinated process development, analytical services, clinical manufacturing, packaging, and logistics. Complex modalities such as biologics, cell and gene therapies, highly potent compounds, and sterile products require specialized facilities, advanced containment, and experienced quality teams. Regulatory expectations for data integrity, comparability, validation, traceability, and supply-chain control are also increasing, making technical depth and inspection readiness central selection criteria.

Artificial Intelligence Is Strengthening Development and Manufacturing Decisions

Artificial intelligence is being applied across investigational new drug CDMO activities, including molecule and process characterization, formulation optimization, analytical data review, deviation investigation, demand planning, and equipment maintenance. Machine-learning tools can help identify process variables and improve the prioritization of experiments, while natural-language systems can support document review and knowledge retrieval. Adoption remains dependent on data quality, model validation, cybersecurity, human oversight, and compliance with applicable requirements for computerized systems and electronic records.

Regional Dynamics Reflect Different Scientific, Regulatory, and Manufacturing Strengths

North America combines strong biopharmaceutical innovation with mature clinical-trial infrastructure and demanding regulatory expectations. Europe benefits from established pharmaceutical capabilities, specialized manufacturing expertise, and cross-border development networks. Asia-Pacific offers expanding scientific capacity, growing clinical-development activity, and increasingly sophisticated manufacturing ecosystems. Latin America is supported by improving research and manufacturing capabilities, although regulatory and logistical conditions vary by country. The Middle East is investing in life-science infrastructure and healthcare resilience, while Africa presents emerging opportunities alongside constraints involving specialized workforce availability, infrastructure, and regulatory capacity.

Economic and Security Alliances Shape Outsourcing Priorities

ASEAN economies are developing complementary capabilities in pharmaceutical manufacturing, clinical research, and regional supply chains. BRICS members span major scientific, manufacturing, and patient-population resources, but differ substantially in regulatory systems and infrastructure. The European Union supports harmonized regulatory coordination while retaining national implementation requirements. G7 countries contribute advanced research, specialized manufacturing, and stringent quality systems. GCC states are strengthening healthcare and pharmaceutical self-sufficiency, whereas NATO members are increasingly attentive to resilient, secure, and diversified medical-product supply chains.

Country Capabilities Vary Across Innovation, Regulation, and Production Scale

The United States and Canada offer deep biotechnology ecosystems, advanced clinical infrastructure, and high regulatory scrutiny. Germany, France, Italy, Spain, and the United Kingdom provide strong pharmaceutical research, manufacturing, and specialist service capabilities within varied national frameworks. China, Japan, South Korea, India, and Australia combine expanding development expertise with distinct regulatory and operational environments. Brazil and Mexico are important Latin American hubs with growing clinical and manufacturing capabilities. Russia retains scientific and industrial capacity, while market access, compliance, and international supply-chain conditions require careful assessment.

Prioritize Technical Fit, Quality Resilience, and Transparent Partnership Models

Industry leaders should match CDMO selection to modality-specific capabilities, development stage, containment needs, sterile-processing requirements, and analytical complexity. Due diligence should assess inspection history, quality systems, data integrity, change control, capacity visibility, workforce depth, business continuity, and technology-transfer performance. Sponsors should establish clear governance, quality agreements, milestone ownership, and escalation pathways early. They should also use AI selectively under validated controls, maintain dual-source or contingency options for critical inputs where practical, and evaluate regional partners against regulatory, logistics, and geopolitical requirements.

Methodology Combines Structured Market Framing With Evidence-Based Industry Analysis

This executive summary uses the defined investigational new drug CDMO market scope and organizes findings across service requirements, technology adoption, regulatory conditions, geography, and economic groupings. Insights are synthesized from established industry practices and publicly documented considerations relevant to clinical development and pharmaceutical manufacturing, including modality complexity, quality management, supply-chain resilience, and digital transformation. No market estimates, market shares, forecasts, or company-specific claims are used.

Executional Excellence Will Define Investigational New Drug CDMO Partnerships

Investigational new drug CDMOs are becoming strategic development partners rather than capacity-only suppliers. Success will depend on the ability to combine specialized science, reliable clinical manufacturing, robust analytics, regulatory discipline, and resilient operations. Sponsors that align outsourcing decisions with product complexity, evidence requirements, geographic risk, and long-term technology-transfer needs will be better positioned to advance candidates efficiently and compliantly.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Investigational New Drug CDMO Market, by Service Type

  • 7.1. Introduction
  • 7.2. Analytical Testing
    • 7.2.1. Method Development And Validation
    • 7.2.2. Release Testing
    • 7.2.3. Stability Studies
  • 7.3. Clinical Trial Material Manufacturing
    • 7.3.1. Phase I/II Material
    • 7.3.2. Phase III Material
  • 7.4. Commercial Manufacturing
    • 7.4.1. Batch Manufacturing
    • 7.4.2. Continuous Manufacturing
  • 7.5. Formulation Development
    • 7.5.1. Lyophilized Formulation
    • 7.5.2. Parenteral Formulation
    • 7.5.3. Solid Dosage Form
  • 7.6. Packaging And Labeling
  • 7.7. Regulatory Support
    • 7.7.1. CMC Documentation
    • 7.7.2. IND Filing Support

8. Investigational New Drug CDMO Market, by Molecule Type

  • 8.1. Introduction
  • 8.2. Biologics
    • 8.2.1. Cell Therapy
    • 8.2.2. Monoclonal Antibodies
      • 8.2.2.1. Antibody Drug Conjugates
      • 8.2.2.2. Biosimilars
    • 8.2.3. Recombinant Proteins
    • 8.2.4. Vaccines
  • 8.3. Gene Therapy
  • 8.4. Peptides
  • 8.5. Small Molecules

9. Investigational New Drug CDMO Market, by Therapeutic Area

  • 9.1. Introduction
  • 9.2. Cardiovascular
  • 9.3. Central Nervous System
  • 9.4. Immunology
  • 9.5. Infectious Diseases
  • 9.6. Oncology
    • 9.6.1. Hematological Malignancies
    • 9.6.2. Solid Tumors

10. Investigational New Drug CDMO Market, by Scale

  • 10.1. Introduction
  • 10.2. Commercial
  • 10.3. Phase I/II
  • 10.4. Phase III
  • 10.5. Preclinical

11. Investigational New Drug CDMO Market, by Manufacturing Type

  • 11.1. Introduction
  • 11.2. Batch
  • 11.3. Continuous

12. Investigational New Drug CDMO Market, by Licensing Model

  • 12.1. Introduction
  • 12.2. Collaborative Research
  • 12.3. Fee-for-Service
  • 12.4. Technology Transfer

13. Investigational New Drug CDMO Market, by Customer Type

  • 13.1. Introduction
  • 13.2. Academic Institutions
  • 13.3. Biotech Companies
  • 13.4. Pharmaceutical Companies
  • 13.5. Virtual Pharma

14. Investigational New Drug CDMO Market, by Region

  • 14.1. Introduction
  • 14.2. Asia-Pacific
  • 14.3. North America
  • 14.4. Latin America
  • 14.5. Europe
  • 14.6. Middle East
  • 14.7. Africa

15. Investigational New Drug CDMO Market, by Group

  • 15.1. Introduction
  • 15.2. ASEAN
  • 15.3. GCC
  • 15.4. European Union
  • 15.5. BRICS
  • 15.6. G7
  • 15.7. NATO

16. Investigational New Drug CDMO Market, by Country

  • 16.1. Introduction
  • 16.2. United States
  • 16.3. Canada
  • 16.4. Mexico
  • 16.5. Brazil
  • 16.6. United Kingdom
  • 16.7. Germany
  • 16.8. France
  • 16.9. Russia
  • 16.10. Italy
  • 16.11. Spain
  • 16.12. China
  • 16.13. India
  • 16.14. Japan
  • 16.15. Australia
  • 16.16. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. Market Concentration Analysis, 2025
    • 17.2.1. Concentration Ratio (CR)
    • 17.2.2. Herfindahl Hirschman Index (HHI)
  • 17.3. Recent Developments & Impact Analysis, 2025
  • 17.4. Product Portfolio Analysis, 2025
  • 17.5. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Adragos Pharma GmbH
  • 18.2. AGC Biologics Inc.
  • 18.3. Asymchem Laboratories Tianjin Co. Ltd.
  • 18.4. Boehringer Ingelheim International GmbH
  • 18.5. Cambrex Corporation
  • 18.6. Catalent Inc.
  • 18.7. Charles River Laboratories International Inc.
  • 18.8. CordenPharma International GmbH
  • 18.9. Dishman Carbogen Amcis Limited
  • 18.10. Eurofins Scientific SE
  • 18.11. Evotec SE
  • 18.12. Fujifilm Diosynth Biotechnologies Inc.
  • 18.13. IQVIA Holdings Inc.
  • 18.14. Laboratory Corporation of America Holdings
  • 18.15. Lonza Group AG
  • 18.16. PCI Pharma Services Inc.
  • 18.17. Piramal Pharma Limited
  • 18.18. Quotient Sciences Ltd.
  • 18.19. Recipharm AB
  • 18.20. Samsung Biologics Co. Ltd.
  • 18.21. Siegfried Holding AG
  • 18.22. Syneos Health Inc.
  • 18.23. Syngene International Ltd.
  • 18.24. Thermo Fisher Scientific Inc.
  • 18.25. WuXi Biologics (Cayman) Inc.

19. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Investigational New Drug CDMO Market, Years Considered for the Study
  • FIGURE 2. Global Investigational New Drug CDMO Market, Research Design
  • FIGURE 3. Global Investigational New Drug CDMO Market, Research Framework
  • FIGURE 4. Global Investigational New Drug CDMO Market, Data Triangulation
  • FIGURE 5. Global Investigational New Drug CDMO Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Investigational New Drug CDMO Market Size, by Service Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Investigational New Drug CDMO Market Size, by Service Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Investigational New Drug CDMO Market Size, by Molecule Type, 2025 vs 2032 (%)
  • FIGURE 9. Global Investigational New Drug CDMO Market Size, by Molecule Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Investigational New Drug CDMO Market Size, by Therapeutic Area, 2025 vs 2032 (%)
  • FIGURE 11. Global Investigational New Drug CDMO Market Size, by Therapeutic Area, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Investigational New Drug CDMO Market Size, by Scale, 2025 vs 2032 (%)
  • FIGURE 13. Global Investigational New Drug CDMO Market Size, by Scale, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Investigational New Drug CDMO Market Size, by Manufacturing Type, 2025 vs 2032 (%)
  • FIGURE 15. Global Investigational New Drug CDMO Market Size, by Manufacturing Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Investigational New Drug CDMO Market Size, by Licensing Model, 2025 vs 2032 (%)
  • FIGURE 17. Global Investigational New Drug CDMO Market Size, by Licensing Model, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Investigational New Drug CDMO Market Size, by Customer Type, 2025 vs 2032 (%)
  • FIGURE 19. Global Investigational New Drug CDMO Market Size, by Customer Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global Investigational New Drug CDMO Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 21. Global Investigational New Drug CDMO Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 22. Global Investigational New Drug CDMO Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global Investigational New Drug CDMO Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 24. Global Investigational New Drug CDMO Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 25. Global Investigational New Drug CDMO Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Investigational New Drug CDMO Market Segmentation & Coverage
  • TABLE 2. Global Investigational New Drug CDMO Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Investigational New Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 4. Global Analytical Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Analytical Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Analytical Testing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Method Development And Validation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Method Development And Validation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Method Development And Validation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Release Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Release Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Release Testing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Stability Studies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Stability Studies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Stability Studies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Clinical Trial Material Manufacturing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Clinical Trial Material Manufacturing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Clinical Trial Material Manufacturing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Phase I/II Material Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Phase I/II Material Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Phase I/II Material Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Phase III Material Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Phase III Material Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Phase III Material Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Commercial Manufacturing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Commercial Manufacturing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Commercial Manufacturing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Batch Manufacturing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Batch Manufacturing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Batch Manufacturing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Continuous Manufacturing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Continuous Manufacturing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Continuous Manufacturing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Formulation Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Formulation Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Formulation Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Lyophilized Formulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Lyophilized Formulation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Lyophilized Formulation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Parenteral Formulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global Parenteral Formulation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global Parenteral Formulation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global Solid Dosage Form Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global Solid Dosage Form Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global Solid Dosage Form Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Packaging And Labeling Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global Packaging And Labeling Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global Packaging And Labeling Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global Regulatory Support Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 50. Global Regulatory Support Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 51. Global Regulatory Support Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 52. Global CMC Documentation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 53. Global CMC Documentation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 54. Global CMC Documentation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 55. Global IND Filing Support Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global IND Filing Support Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global IND Filing Support Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global Investigational New Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 59. Global Biologics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 60. Global Biologics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 61. Global Biologics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 62. Global Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 63. Global Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 64. Global Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 65. Global Monoclonal Antibodies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. Global Monoclonal Antibodies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 67. Global Monoclonal Antibodies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 68. Global Antibody Drug Conjugates Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 69. Global Antibody Drug Conjugates Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 70. Global Antibody Drug Conjugates Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 71. Global Biosimilars Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Global Biosimilars Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 73. Global Biosimilars Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 74. Global Recombinant Proteins Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 75. Global Recombinant Proteins Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 76. Global Recombinant Proteins Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 77. Global Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 78. Global Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 79. Global Vaccines Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 80. Global Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 81. Global Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 82. Global Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 83. Global Peptides Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. Global Peptides Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 85. Global Peptides Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 86. Global Small Molecules Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. Global Small Molecules Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 88. Global Small Molecules Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 89. Global Investigational New Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 90. Global Cardiovascular Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 91. Global Cardiovascular Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 92. Global Cardiovascular Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 93. Global Central Nervous System Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 94. Global Central Nervous System Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 95. Global Central Nervous System Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 96. Global Immunology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 97. Global Immunology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 98. Global Immunology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 99. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 100. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 101. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 102. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 103. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 104. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 105. Global Hematological Malignancies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 106. Global Hematological Malignancies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 107. Global Hematological Malignancies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 108. Global Solid Tumors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 109. Global Solid Tumors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 110. Global Solid Tumors Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 111. Global Investigational New Drug CDMO Market Size, by Scale, 2017-2032 (USD Million)
  • TABLE 112. Global Commercial Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 113. Global Commercial Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 114. Global Commercial Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 115. Global Phase I/II Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 116. Global Phase I/II Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 117. Global Phase I/II Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 118. Global Phase III Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 119. Global Phase III Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 120. Global Phase III Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 121. Global Preclinical Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 122. Global Preclinical Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 123. Global Preclinical Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 124. Global Investigational New Drug CDMO Market Size, by Manufacturing Type, 2017-2032 (USD Million)
  • TABLE 125. Global Batch Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 126. Global Batch Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 127. Global Batch Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 128. Global Continuous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 129. Global Continuous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 130. Global Continuous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 131. Global Investigational New Drug CDMO Market Size, by Licensing Model, 2017-2032 (USD Million)
  • TABLE 132. Global Collaborative Research Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 133. Global Collaborative Research Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 134. Global Collaborative Research Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 135. Global Fee-for-Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 136. Global Fee-for-Service Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 137. Global Fee-for-Service Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 138. Global Technology Transfer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 139. Global Technology Transfer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 140. Global Technology Transfer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 141. Global Investigational New Drug CDMO Market Size, by Customer Type, 2017-2032 (USD Million)
  • TABLE 142. Global Academic Institutions Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 143. Global Academic Institutions Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 144. Global Academic Institutions Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 145. Global Biotech Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 146. Global Biotech Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 147. Global Biotech Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 148. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 149. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 150. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 151. Global Virtual Pharma Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 152. Global Virtual Pharma Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 153. Global Virtual Pharma Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 154. Global Investigational New Drug CDMO Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 155. Asia-Pacific Investigational New Drug CDMO Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 156. Asia-Pacific Investigational New Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 157. Asia-Pacific Investigational New Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 158. Asia-Pacific Investigational New Drug CDMO Market Size, by Clinical Trial Material Manufacturing, 2017-2032 (USD Million)
  • TABLE 159. Asia-Pacific Investigational New Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 160. Asia-Pacific Investigational New Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 161. Asia-Pacific Investigational New Drug CDMO Market Size, by Regulatory Support, 2017-2032 (USD Million)
  • TABLE 162. Asia-Pacific Investigational New Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 163. Asia-Pacific Investigational New Drug CDMO Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 164. Asia-Pacific Investigational New Drug CDMO Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
  • TABLE 165. Asia-Pacific Investigational New Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 166. Asia-Pacific Investigational New Drug CDMO Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 167. Asia-Pacific Investigational New Drug CDMO Market Size, by Scale, 2017-2032 (USD Million)
  • TABLE 168. Asia-Pacific Investigational New Drug CDMO Market Size, by Manufacturing Type, 2017-2032 (USD Million)
  • TABLE 169. Asia-Pacific Investigational New Drug CDMO Market Size, by Licensing Model, 2017-2032 (USD Million)
  • TABLE 170. Asia-Pacific Investigational New Drug CDMO Market Size, by Customer Type, 2017-2032 (USD Million)
  • TABLE 171. North America Investigational New Drug CDMO Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 172. North America Investigational New Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 173. North America Investigational New Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 174. North America Investigational New Drug CDMO Market Size, by Clinical Trial Material Manufacturing, 2017-2032 (USD Million)
  • TABLE 175. North America Investigational New Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 176. North America Investigational New Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 177. North America Investigational New Drug CDMO Market Size, by Regulatory Support, 2017-2032 (USD Million)
  • TABLE 178. North America Investigational New Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 179. North America Investigational New Drug CDMO Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 180. North America Investigational New Drug CDMO Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
  • TABLE 181. North America Investigational New Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 182. North America Investigational New Drug CDMO Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 183. North America Investigational New Drug CDMO Market Size, by Scale, 2017-2032 (USD Million)
  • TABLE 184. North America Investigational New Drug CDMO Market Size, by Manufacturing Type, 2017-2032 (USD Million)
  • TABLE 185. North America Investigational New Drug CDMO Market Size, by Licensing Model, 2017-2032 (USD Million)
  • TABLE 186. North America Investigational New Drug CDMO Market Size, by Customer Type, 2017-2032 (USD Million)
  • TABLE 187. Latin America Investigational New Drug CDMO Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 188. Latin America Investigational New Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 189. Latin America Investigational New Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 190. Latin America Investigational New Drug CDMO Market Size, by Clinical Trial Material Manufacturing, 2017-2032 (USD Million)
  • TABLE 191. Latin America Investigational New Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 192. Latin America Investigational New Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 193. Latin America Investigational New Drug CDMO Market Size, by Regulatory Support, 2017-2032 (USD Million)
  • TABLE 194. Latin America Investigational New Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 195. Latin America Investigational New Drug CDMO Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 196. Latin America Investigational New Drug CDMO Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
  • TABLE 197. Latin America Investigational New Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 198. Latin America Investigational New Drug CDMO Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 199. Latin America Investigational New Drug CDMO Market Size, by Scale, 2017-2032 (USD Million)
  • TABLE 200. Latin America Investigational New Drug CDMO Market Size, by Manufacturing Type, 2017-2032 (USD Million)
  • TABLE 201. Latin America Investigational New Drug CDMO Market Size, by Licensing Model, 2017-2032 (USD Million)
  • TABLE 202. Latin America Investigational New Drug CDMO Market Size, by Customer Type, 2017-2032 (USD Million)
  • TABLE 203. Europe Investigational New Drug CDMO Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 204. Europe Investigational New Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 205. Europe Investigational New Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 206. Europe Investigational New Drug CDMO Market Size, by Clinical Trial Material Manufacturing, 2017-2032 (USD Million)
  • TABLE 207. Europe Investigational New Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 208. Europe Investigational New Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 209. Europe Investigational New Drug CDMO Market Size, by Regulatory Support, 2017-2032 (USD Million)
  • TABLE 210. Europe Investigational New Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 211. Europe Investigational New Drug CDMO Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 212. Europe Investigational New Drug CDMO Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
  • TABLE 213. Europe Investigational New Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 214. Europe Investigational New Drug CDMO Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 215. Europe Investigational New Drug CDMO Market Size, by Scale, 2017-2032 (USD Million)
  • TABLE 216. Europe Investigational New Drug CDMO Market Size, by Manufacturing Type, 2017-2032 (USD Million)
  • TABLE 217. Europe Investigational New Drug CDMO Market Size, by Licensing Model, 2017-2032 (USD Million)
  • TABLE 218. Europe Investigational New Drug CDMO Market Size, by Customer Type, 2017-2032 (USD Million)
  • TABLE 219. Middle East Investigational New Drug CDMO Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 220. Middle East Investigational New Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 221. Middle East Investigational New Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 222. Middle East Investigational New Drug CDMO Market Size, by Clinical Trial Material Manufacturing, 2017-2032 (USD Million)
  • TABLE 223. Middle East Investigational New Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 224. Middle East Investigational New Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 225. Middle East Investigational New Drug CDMO Market Size, by Regulatory Support, 2017-2032 (USD Million)
  • TABLE 226. Middle East Investigational New Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 227. Middle East Investigational New Drug CDMO Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 228. Middle East Investigational New Drug CDMO Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
  • TABLE 229. Middle East Investigational New Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 230. Middle East Investigational New Drug CDMO Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 231. Middle East Investigational New Drug CDMO Market Size, by Scale, 2017-2032 (USD Million)
  • TABLE 232. Middle East Investigational New Drug CDMO Market Size, by Manufacturing Type, 2017-2032 (USD Million)
  • TABLE 233. Middle East Investigational New Drug CDMO Market Size, by Licensing Model, 2017-2032 (USD Million)
  • TABLE 234. Middle East Investigational New Drug CDMO Market Size, by Customer Type, 2017-2032 (USD Million)
  • TABLE 235. Africa Investigational New Drug CDMO Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 236. Africa Investigational New Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 237. Africa Investigational New Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 238. Africa Investigational New Drug CDMO Market Size, by Clinical Trial Material Manufacturing, 2017-2032 (USD Million)
  • TABLE 239. Africa Investigational New Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 240. Africa Investigational New Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 241. Africa Investigational New Drug CDMO Market Size, by Regulatory Support, 2017-2032 (USD Million)
  • TABLE 242. Africa Investigational New Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 243. Africa Investigational New Drug CDMO Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 244. Africa Investigational New Drug CDMO Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
  • TABLE 245. Africa Investigational New Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 246. Africa Investigational New Drug CDMO Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 247. Africa Investigational New Drug CDMO Market Size, by Scale, 2017-2032 (USD Million)
  • TABLE 248. Africa Investigational New Drug CDMO Market Size, by Manufacturing Type, 2017-2032 (USD Million)
  • TABLE 249. Africa Investigational New Drug CDMO Market Size, by Licensing Model, 2017-2032 (USD Million)
  • TABLE 250. Africa Investigational New Drug CDMO Market Size, by Customer Type, 2017-2032 (USD Million)
  • TABLE 251. Global Investigational New Drug CDMO Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 252. ASEAN Investigational New Drug CDMO Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 253. ASEAN Investigational New Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 254. ASEAN Investigational New Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 255. ASEAN Investigational New Drug CDMO Market Size, by Clinical Trial Material Manufacturing, 2017-2032 (USD Million)
  • TABLE 256. ASEAN Investigational New Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 257. ASEAN Investigational New Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 258. ASEAN Investigational New Drug CDMO Market Size, by Regulatory Support, 2017-2032 (USD Million)
  • TABLE 259. ASEAN Investigational New Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 260. ASEAN Investigational New Drug CDMO Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 261. ASEAN Investigational New Drug CDMO Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
  • TABLE 262. ASEAN Investigational New Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 263. ASEAN Investigational New Drug CDMO Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 264. ASEAN Investigational New Drug CDMO Market Size, by Scale, 2017-2032 (USD Million)
  • TABLE 265. ASEAN Investigational New Drug CDMO Market Size, by Manufacturing Type, 2017-2032 (USD Million)
  • TABLE 266. ASEAN Investigational New Drug CDMO Market Size, by Licensing Model, 2017-2032 (USD Million)
  • TABLE 267. ASEAN Investigational New Drug CDMO Market Size, by Customer Type, 2017-2032 (USD Million)
  • TABLE 268. GCC Investigational New Drug CDMO Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 269. GCC Investigational New Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 270. GCC Investigational New Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 271. GCC Investigational New Drug CDMO Market Size, by Clinical Trial Material Manufacturing, 2017-2032 (USD Million)
  • TABLE 272. GCC Investigational New Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 273. GCC Investigational New Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 274. GCC Investigational New Drug CDMO Market Size, by Regulatory Support, 2017-2032 (USD Million)
  • TABLE 275. GCC Investigational New Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 276. GCC Investigational New Drug CDMO Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 277. GCC Investigational New Drug CDMO Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
  • TABLE 278. GCC Investigational New Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 279. GCC Investigational New Drug CDMO Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 280. GCC Investigational New Drug CDMO Market Size, by Scale, 2017-2032 (USD Million)
  • TABLE 281. GCC Investigational New Drug CDMO Market Size, by Manufacturing Type, 2017-2032 (USD Million)
  • TABLE 282. GCC Investigational New Drug CDMO Market Size, by Licensing Model, 2017-2032 (USD Million)
  • TABLE 283. GCC Investigational New Drug CDMO Market Size, by Customer Type, 2017-2032 (USD Million)
  • TABLE 284. European Union Investigational New Drug CDMO Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 285. European Union Investigational New Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 286. European Union Investigational New Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 287. European Union Investigational New Drug CDMO Market Size, by Clinical Trial Material Manufacturing, 2017-2032 (USD Million)
  • TABLE 288. European Union Investigational New Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 289. European Union Investigational New Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 290. European Union Investigational New Drug CDMO Market Size, by Regulatory Support, 2017-2032 (USD Million)
  • TABLE 291. European Union Investigational New Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 292. European Union Investigational New Drug CDMO Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 293. European Union Investigational New Drug CDMO Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
  • TABLE 294. European Union Investigational New Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 295. European Union Investigational New Drug CDMO Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 296. European Union Investigational New Drug CDMO Market Size, by Scale, 2017-2032 (USD Million)
  • TABLE 297. European Union Investigational New Drug CDMO Market Size, by Manufacturing Type, 2017-2032 (USD Million)
  • TABLE 298. European Union Investigational New Drug CDMO Market Size, by Licensing Model, 2017-2032 (USD Million)
  • TABLE 299. European Union Investigational New Drug CDMO Market Size, by Customer Type, 2017-2032 (USD Million)
  • TABLE 300. BRICS Investigational New Drug CDMO Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 301. BRICS Investigational New Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 302. BRICS Investigational New Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 303. BRICS Investigational New Drug CDMO Market Size, by Clinical Trial Material Manufacturing, 2017-2032 (USD Million)
  • TABLE 304. BRICS Investigational New Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 305. BRICS Investigational New Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 306. BRICS Investigational New Drug CDMO Market Size, by Regulatory Support, 2017-2032 (USD Million)
  • TABLE 307. BRICS Investigational New Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 308. BRICS Investigational New Drug CDMO Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 309. BRICS Investigational New Drug CDMO Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
  • TABLE 310. BRICS Investigational New Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 311. BRICS Investigational New Drug CDMO Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 312. BRICS Investigational New Drug CDMO Market Size, by Scale, 2017-2032 (USD Million)
  • TABLE 313. BRICS Investigational New Drug CDMO Market Size, by Manufacturing Type, 2017-2032 (USD Million)
  • TABLE 314. BRICS Investigational New Drug CDMO Market Size, by Licensing Model, 2017-2032 (USD Million)
  • TABLE 315. BRICS Investigational New Drug CDMO Market Size, by Customer Type, 2017-2032 (USD Million)
  • TABLE 316. G7 Investigational New Drug CDMO Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 317. G7 Investigational New Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 318. G7 Investigational New Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 319. G7 Investigational New Drug CDMO Market Size, by Clinical Trial Material Manufacturing, 2017-2032 (USD Million)
  • TABLE 320. G7 Investigational New Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 321. G7 Investigational New Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)
  • TABLE 322. G7 Investigational New Drug CDMO Market Size, by Regulatory Support, 2017-2032 (USD Million)
  • TABLE 323. G7 Investigational New Drug CDMO Market Size, by Molecule Type, 2017-2032 (USD Million)
  • TABLE 324. G7 Investigational New Drug CDMO Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 325. G7 Investigational New Drug CDMO Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
  • TABLE 326. G7 Investigational New Drug CDMO Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 327. G7 Investigational New Drug CDMO Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 328. G7 Investigational New Drug CDMO Market Size, by Scale, 2017-2032 (USD Million)
  • TABLE 329. G7 Investigational New Drug CDMO Market Size, by Manufacturing Type, 2017-2032 (USD Million)
  • TABLE 330. G7 Investigational New Drug CDMO Market Size, by Licensing Model, 2017-2032 (USD Million)
  • TABLE 331. G7 Investigational New Drug CDMO Market Size, by Customer Type, 2017-2032 (USD Million)
  • TABLE 332. NATO Investigational New Drug CDMO Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 333. NATO Investigational New Drug CDMO Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 334. NATO Investigational New Drug CDMO Market Size, by Analytical Testing, 2017-2032 (USD Million)
  • TABLE 335. NATO Investigational New Drug CDMO Market Size, by Clinical Trial Material Manufacturing, 2017-2032 (USD Million)
  • TABLE 336. NATO Investigational New Drug CDMO Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 337. NATO Investigational New Drug CDMO Market Size, by Formulation Development, 2017-2032 (USD Million)